Published in Antimicrob Agents Chemother on August 11, 2008
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica (2012) 1.80
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep (2010) 1.31
Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother (2008) 1.15
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob Agents Chemother (2009) 1.00
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica (2013) 0.93
Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis. Antimicrob Agents Chemother (2013) 0.91
Invasive mold infections: virulence and pathogenesis of mucorales. Int J Microbiol (2011) 0.88
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother (2010) 0.87
Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med (2014) 0.85
NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning. PLoS Comput Biol (2016) 0.85
Multimodal surgical and medical treatment for extensive rhinocerebral mucormycosis in an elderly diabetic patient: a case report and literature review. Case Rep Med (2014) 0.82
Human fungal pathogens of mucorales and entomophthorales. Cold Spring Harb Perspect Med (2014) 0.82
Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice. Antimicrob Agents Chemother (2009) 0.79
Mucormycosis, pseudallescheriasis, and other uncommon mold infections. Proc Am Thorac Soc (2010) 0.79
Gastrointestinal Mucormycosis following a Streptococcus pyogenes Toxic Shock Syndrome in a Previously Healthy Patient: A Case Report. Case Rep Infect Dis (2012) 0.75
Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis (2005) 13.97
Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev (2005) 5.77
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis (2006) 3.57
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother (2002) 2.89
Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother (2006) 2.65
Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother (2003) 2.09
Treatment of zygomycosis: current and new options. J Antimicrob Chemother (2008) 1.86
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother (2007) 1.85
Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. Mycoses (2006) 1.20
Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice. Antimicrob Agents Chemother (2003) 1.16
Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles. Antimicrob Agents Chemother (2000) 1.01
Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother (2006) 0.94
Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J Clin Microbiol (2005) 2.83
Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J Clin Microbiol (2007) 2.57
Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus. J Clin Microbiol (2005) 2.52
Molecular phylogeny of Sporothrix schenckii. J Clin Microbiol (2006) 1.76
Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother (2006) 1.74
Fusarium oxysporum as a multihost model for the genetic dissection of fungal virulence in plants and mammals. Infect Immun (2004) 1.67
Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J Clin Microbiol (2007) 1.66
Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol (2009) 1.61
In vitro antifungal susceptibilities of five species of sporothrix. Antimicrob Agents Chemother (2007) 1.60
Molecular identification and in vitro response to antifungal drugs of clinical isolates of Exserohilum. Antimicrob Agents Chemother (2012) 1.51
Molecular phylogenetic diversity of the emerging mucoralean fungus Apophysomyces: proposal of three new species. Rev Iberoam Micol (2010) 1.40
In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol (2004) 1.39
Sporothrix luriei: a rare fungus from clinical origin. Med Mycol (2008) 1.38
Molecular and morphological identification of Colletotrichum species of clinical interest. J Clin Microbiol (2004) 1.35
Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob Agents Chemother (2007) 1.31
PCR protocol for specific identification of Candida nivariensis, a recently described pathogenic yeast. J Clin Microbiol (2005) 1.25
Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes. J Clin Microbiol (2002) 1.23
In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob Agents Chemother (2004) 1.22
Sporothrix globosa, a pathogenic fungus with widespread geographical distribution. Rev Iberoam Micol (2009) 1.21
Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs. Antimicrob Agents Chemother (2004) 1.16
Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice. Antimicrob Agents Chemother (2003) 1.16
Presence of Arcobacter spp. in environmental waters correlates with high levels of fecal pollution. Environ Microbiol (2008) 1.15
Prevalence of Arcobacter in meat and shellfish. J Food Prot (2009) 1.14
Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med Mycol (2011) 1.13
Actinomucor elegans var. kuwaitiensis isolated from the wound of a diabetic patient. Antonie Van Leeuwenhoek (2008) 1.12
Scopulariopsis, a poorly known opportunistic fungus: spectrum of species in clinical samples and in vitro responses to antifungal drugs. J Clin Microbiol (2013) 1.11
Saksenaea vasiformis infections: case report and literature review. Mycopathologia (2006) 1.09
Genus Hamigera, six new species and multilocus DNA sequence based phylogeny. Mycologia (2010) 1.08
In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases. Antimicrob Agents Chemother (2005) 1.07
Role of the white collar 1 photoreceptor in carotenogenesis, UV resistance, hydrophobicity, and virulence of Fusarium oxysporum. Eukaryot Cell (2008) 1.06
HapX-mediated iron homeostasis is essential for rhizosphere competence and virulence of the soilborne pathogen Fusarium oxysporum. Plant Cell (2012) 1.06
The velvet complex governs mycotoxin production and virulence of Fusarium oxysporum on plant and mammalian hosts. Mol Microbiol (2012) 1.06
Two new species of Mucor from clinical samples. Med Mycol (2010) 1.05
Genotyping of Scedosporium species: a review of molecular approaches. Med Mycol (2008) 1.05
Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis. Antimicrob Agents Chemother (2005) 1.05
Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother (2009) 1.05
Genotyping of 44 isolates of Fusarium solani, the main agent of fungal keratitis in Brazil. J Clin Microbiol (2004) 1.04
Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn Microbiol Infect Dis (2004) 1.04
In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis (2004) 1.02
Potential virulence and antimicrobial susceptibility of Aeromonas popoffii recovered from freshwater and seawater. FEMS Immunol Med Microbiol (2002) 1.02
Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus. J Antimicrob Chemother (2008) 1.01
Combined antifungal therapy in a murine model of disseminated infection by Cladophialophora bantiana. Med Mycol (2008) 1.01
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob Agents Chemother (2009) 1.00
In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp. Antimicrob Agents Chemother (2005) 1.00
Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother (2002) 0.99
Clinical treatment of corneal infection due to Fonsecaea pedrosoi--case report. Arq Bras Oftalmol (2005) 0.98
In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. Antimicrob Agents Chemother (2003) 0.98
A comprehensive phylogeny of Neurospora reveals a link between reproductive mode and molecular evolution in fungi. Mol Phylogenet Evol (2011) 0.97
Molecular phylogeny of Coniochaetales. Mycol Res (2006) 0.96
Less-frequent Fusarium species of clinical interest: correlation between morphological and molecular identification and antifungal susceptibility. J Clin Microbiol (2009) 0.96
Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis. Antimicrob Agents Chemother (2002) 0.95
Different virulence of the species of the Pseudallescheria boydii complex. Med Mycol (2008) 0.95
In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole. Antimicrob Agents Chemother (2012) 0.95
Heterothallism in Scedosporium apiospermum and description of its teleomorph Pseudallescheria apiosperma sp. nov. Med Mycol (2010) 0.94
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. Antimicrob Agents Chemother (2008) 0.93
Saccharomyces cerevisiae vaginitis: microbiology and in vitro antifungal susceptibility. Mycopathologia (2011) 0.93
Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother (2007) 0.93
Molecular identification and antifungal susceptibility testing of clinical isolates of the Candida rugosa species complex and proposal of the new species Candida neorugosa. J Clin Microbiol (2012) 0.92
New pyrenochaeta species causing keratitis. J Clin Microbiol (2009) 0.92
A new 16S rDNA-RFLP method for the discrimination of the accepted species of Arcobacter. Diagn Microbiol Infect Dis (2007) 0.92
Apophysomyces variabilis infections in humans. Emerg Infect Dis (2011) 0.92
Rho1 has distinct functions in morphogenesis, cell wall biosynthesis and virulence of Fusarium oxysporum. Cell Microbiol (2008) 0.92
Pyrenochaeta keratinophila sp. nov., isolated from an ocular infection in Spain. Rev Iberoam Micol (2009) 0.91
Cladophialophora psammophila, a novel species of Chaetothyriales with a potential use in the bioremediation of volatile aromatic hydrocarbons. Fungal Biol (2011) 0.91
Phialemoniopsis, a new genus of Sordariomycetes, and new species of Phialemonium and Lecythophora. Mycologia (2012) 0.91
Genotyping and in vitro antifungal susceptibility of Neoscytalidium dimidiatum isolates from different origins. Int J Antimicrob Agents (2009) 0.91
Combined antifungal therapy in a murine infection by Candida glabrata. J Antimicrob Chemother (2006) 0.91
Isolation of Candida africana, probable atypical strains of Candida albicans, from a patient with vaginitis. Med Mycol (2008) 0.91
Comparison of in vitro antifungal susceptibilities of conidia and hyphae of dermatophytes with thick-wall macroconidia. Antimicrob Agents Chemother (2003) 0.90
Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. Antimicrob Agents Chemother (2009) 0.90
Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. Antimicrob Agents Chemother (2009) 0.90